US | Jotup

CORRECTING AND REPLACING: NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

Retrieved on:

Monday, November 6, 2023

ASX, U.S. Department of Energy, Office of Inspector General, MESC, US, ATVM, NVX, Workforce, United, Engineering, Admiral, RET, USN, DOE, BIL, U.S. Department of Defense Strategy for Operating in Cyberspace, Forest Law Enforcement and Governance Program, Renewable energy

BRISBANE, Australia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company, today announced that its NOVONIX Anode Materials division finalized its US$100 million grant award from the U.S. Department of Energy (DOE) to expand domestic production of high-performance, synthetic graphite anode materials at its Riverside facility in Chattanooga, Tennessee.

Key Points:

The DOE grant funding will support the installation and commissioning of equipment to produce the targeted 20,000 tpa of capacity from Riverside.
“We are excited to complete the award negotiation with the DOE and expand the capacity of our Riverside facility.
NOVONIX also continues to advance plans for a new production facility with an initial production target of at least 30,000 tpa.
This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert J. Natter, USN Ret.

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Retrieved on:

Monday, November 6, 2023

TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, newly-formed subsidiary, Revive Diagnostics Inc., today announced that it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1.

Key Points:

Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Revive Therapeutics and Lawson will work together in completing the development of a qELISA laboratory test kit and a lateral flow assay point of care device for rapid testing of long COVID.
In addition, Revive Therapeutics will evaluate the potential of the long COVID test as a companion to Bucillamine – a potential treatment for long COVID disease.
Under the terms of the agreement, Revive Diagnostics Inc., a subsidiary of Revive Therapeutics, has gained exclusive worldwide rights to intellectual property for the development and commercialization of novel blood biomarkers that characterize long COVID disease.

Solaris Appoints COO to Lead Warintza Project; US$80 Million Financing Package Well Advanced to Fund Studies and Permitting

Retrieved on:

Monday, November 6, 2023

SLS, Hudbay, Documentation, Area studies, Mining, National University of Engineering, US, Pedigree, Project, Engineering, National instrument, 1995 Skoal Bandit Copper World Classic, National university, Constância, TSX, Technical Report Archive & Image Library, Management

In addition, the Company reports that it is in advanced discussions on a US$80 million offtake financing package to fund the Project through studies and permitting.

Key Points:

In addition, the Company reports that it is in advanced discussions on a US$80 million offtake financing package to fund the Project through studies and permitting.
Javier is a highly successful leader with a proven record of achievement that is directly relevant to our plans for Warintza.
Prior to this, Mr. Toro held various management positions in mine operations in the areas of geotechnical, hydrogeological, mine operations, and mine planning.
Mr. Toro holds a Bachelor of Mining Engineering with Honors from the National University of Engineering in Lima, Peru.

Pacific Green Reaches Financial Close for £120 Million (US$146 Million) of Funding for Its 249 MW / 373.5 MWh Sheaf Energy Park Battery Development

Retrieved on:

Friday, November 3, 2023

US, DE, NatWest, Pacific Green, OTCQB, Energy Park, Saint Paul, Facility, Growth, UKIB, Renewable energy

Dover, DE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Pacific Green Technologies, Inc. ("Pacific Green", OTCQB: PGTK) announces that it has reached financial close on a £120 million (US$146 million) senior debt facility (the “Facility”) for Pacific Green’s 249 MW / 373.5 MWh Sheaf Energy Park battery energy storage system in Kent, England (“Sheaf Energy Park”).

Key Points:

Dover, DE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Pacific Green Technologies, Inc. ("Pacific Green", OTCQB: PGTK) announces that it has reached financial close on a £120 million (US$146 million) senior debt facility (the “Facility”) for Pacific Green’s 249 MW / 373.5 MWh Sheaf Energy Park battery energy storage system in Kent, England (“Sheaf Energy Park”).
The Facility is provided by a two-bank syndicate, with National Westminster Bank plc (“NatWest”) and UK Infrastructure Bank Limited (“UKIB”) contributing £60 million (US$73 million) each.
The Facility will be used to fund the development and construction of Sheaf Energy Park, following which repayment will occur on a 10 year amortization profile upon the start of commercial operations.
Scott Poulter, Pacific Green’s CEO, commented: “Sheaf Energy Park represents one of the largest project-financed battery energy storage systems in the world.

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2023

Retrieved on:

Thursday, November 2, 2023

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2023.

Key Points:

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights:
Revenue was $65.3 million, an increase of 14% from $57.4 million in Q3 2022.
“Revenue and adjusted EBITDA for the quarter were both above the high-end of our guidance ranges for the quarter,” said Robert Musslewhite, CEO of Definitive Healthcare.
Definitive Healthcare will host a conference call on November 2, 2023, at 5:00 p.m. (Eastern Time) to discuss the Company's full financial results and current business outlook.

Luckin Coffee Inc. Announces Third Quarter 2023 Financial Results

Retrieved on:

Wednesday, November 1, 2023

Coffee, US, OTC, GAAP, Research, Advertising, Growth, Marketing, Partnership, ADS, Depreciation, Luckin Coffee, Investment, Video game, Retail, Cryptocurrency, Reinsurance

BEIJING, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended September 30, 2023.

Key Points:

More Than 2,400 Net New Store Openings; Ended Quarter With More Than 13,000 Stores
BEIJING, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended September 30, 2023.
Same-store sales growth for self-operated stores in the third quarter was 19.9%, compared to 19.4% in the same quarter of 2022.
Revenues from partnership stores in the third quarter were RMB1,840.8 million (US$252.3 million), representing an increase of 104.7% from RMB899.1 million in the same quarter of 2022.
Total net revenues were RMB7,200.0 million (US$986.8 million) in the third quarter of 2023, representing an increase of 84.9% from RMB3,894.6 million in the same quarter of 2022.

NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

Retrieved on:

Tuesday, October 31, 2023

ASX, U.S. Department of Energy, Office of Inspector General, US, ATVM, NVX, Engineering, Admiral, RET, USN, DOE, BIL, U.S. Department of Defense Strategy for Operating in Cyberspace, Forest Law Enforcement and Governance Program, Renewable energy

BRISBANE, Australia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company, today announced that its NOVONIX Anode Materials division finalized its US$100 million grant award from the U.S. Department of Energy (DOE) to expand domestic production of high-performance, synthetic graphite anode materials at its Riverside facility in Chattanooga, Tennessee.

Key Points:

The DOE grant funding will support the installation and commissioning of equipment to produce the targeted 20,000 tpa of capacity from Riverside.
In addition to the US$100 million DOE grant funding, the Company expects its cash position, customer revenues, additional government programs, strategic partners and other capital sources to fund planned growth.
“We are excited to complete the award negotiation with the DOE and expand the capacity of our Riverside facility.
NOVONIX also continues to advance plans for a new production facility with an initial production target of at least 30,000 tpa.

Centerra Gold Announces Quarterly Dividend of C$0.07 per Common Share

Retrieved on:

Tuesday, October 31, 2023

CG, Policy, NYSE, TSX, US, Holding company

TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) announced today that its Board of Directors has approved a quarterly dividend of C$0.07 per common share – approximately C$15.0 million or US$11 million.

Key Points:

TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) announced today that its Board of Directors has approved a quarterly dividend of C$0.07 per common share – approximately C$15.0 million or US$11 million.
The quarterly dividend is payable on November 29, 2023, to shareholders of record on November 15, 2023.
The dividend is an eligible dividend for Canadian income tax purposes.
In accordance with Centerra’s dividend policy, the timing and quantum of dividends are to be determined by the Board of Directors from time-to-time based on, among other things, the Company’s operating results, cash flow and financial conditions, current and anticipated capital requirements, and general business conditions.

PM Hasina and GCA CEO meet ahead of COP28; commit to drive $1bn in climate finance in support of Mujib Climate Prosperity Plan

Retrieved on:

Tuesday, October 31, 2023

GCA is committed to leveraging its resources to work with the Government and its partners to design, finance, and implement adaptation solutions to sustain this path to prosperity.

Key Points:

GCA is committed to leveraging its resources to work with the Government and its partners to design, finance, and implement adaptation solutions to sustain this path to prosperity.
The Government of Bangladesh spends an estimated US$1.2bn each year to finance adaptation needs.
However, the financing needs identified in the government’s Mujib Climate Prosperity Plan (MCPP) to address the threat of climate change exceed US$8.5bn each year.
Without greater funding climate change will undermine Bangladesh’s strong development trajectory and the poorest will be hardest hit.

Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership

Retrieved on:

Tuesday, October 31, 2023

BioScience Research Collaborative, Therapy, GPCR, Medicine, Drug discovery, Research, US, Roche, Fine chemical, Genentech

Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche Group.

Key Points:

Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche Group.
The discovery-based payment is related to progression of a potential first-in-class project targeting an undisclosed G protein-coupled receptor (“GPCR”).
Under the terms of the agreement, Sosei Heptares is eligible to receive future milestone payments from Genentech, which in total may exceed US$1 billion upon achieving pre-specified research, development and commercialization events.
Dr. Matt Barnes, President of Heptares Therapeutics and Head of UK R&D at Sosei Heptares, said: “We are extremely pleased to see the progression of this novel first-in-class project.